Skip to main content
RIBOMIC Inc. logo

RIBOMIC Inc. — Investor Relations & Filings

Ticker · 4591 ISIN · JP3974850004 T Manufacturing
Filings indexed 68 across all filing types
Latest filing 2026-05-20 Share Issue/Capital Cha…
Country JP Japan
Listing T 4591

About RIBOMIC Inc.

https://www.ribomic.com/eng/

RIBOMIC Inc. is a biopharmaceutical company engaged in the discovery and development of novel molecular-targeted therapeutics using its proprietary RNA aptamer technology. The company's core drug discovery platform, the RiboART System (Ribomic Aptamer Refined Therapeutics System), enables the creation of aptamers that bind to target molecules with high affinity and specificity. RIBOMIC's development pipeline focuses on addressing significant unmet medical needs in various therapeutic areas. Key clinical programs include potential treatments for ophthalmic conditions, such as wet age-related macular degeneration, and rare genetic disorders like achondroplasia.

Recent filings

Filing Released Lang Actions
資本金及び資本準備金の額の減少並びに剰余金の処分に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is a formal notice announcing the board’s decision to propose a reduction in share capital and capital reserves and the appropriation of surplus at the upcoming shareholders’ meeting. It details changes in capital stock amounts, reserve transfers, and the schedule for creditor objection and effectiveness. This is clearly a capital change announcement rather than an actual financial report, management commentary, or unrelated regulatory filing. Therefore, it fits the “Share Issue/Capital Change” category (Code: SHA).
2026-05-20 Japanese
会計監査人の異動に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate disclosure titled “会計監査人の異動に関するお知らせ,” notifying shareholders of the proposed change of the external accounting auditor at the upcoming shareholders’ meeting. It contains no financial statements or audit opinions itself, and it is an announcement of an auditor appointment/retirement, not the audit report. There is no specific category for auditor changes, so it falls under miscellaneous regulatory announcements.
2026-05-20 Japanese
取締役(監査等委員である取締役を除く)及び取締役(監査等委員である取締役)の報酬限度額に関するお知らせ
Remuneration Information Classification · 80% confidence The document is a formal corporate announcement regarding the proposed remuneration limits for directors (both non‐audit committee members and audit committee members) to be submitted at the upcoming Annual Shareholders’ Meeting. It does not contain financial statements or meeting minutes, but it specifically details executive/director compensation policy and limits. This falls squarely under ‘Remuneration Information’ (DEF 14A).
2026-05-20 Japanese
定款一部変更に関するお知らせ
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a formal notice (“お知らせ”) of partial amendments to the company’s Articles of Incorporation to be proposed at its 23rd Annual General Meeting on June 23, 2026, detailing agenda items for shareholder approval (authorized share increase and transition to an audit-committee company). This is pre-meeting informational material sent to shareholders to solicit their votes on these proposals, which aligns with the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-20 Japanese
臨時報告書
Regulatory Filings Classification · 82% confidence The document is a Japanese ‘臨時報告書’ (Extraordinary Report) submitted under the Financial Instruments and Exchange Act. It announces the change of external auditors (appointment and resignation) and provides required disclosures. It does not contain actual financial statements, nor is it a Q1/Q2 report or an annual report, but rather a regulatory disclosure notice. This fits the catch-all category “Regulatory Filings” (RNS).
2026-05-20 Japanese
2026年3月期決算説明会資料
Investor Presentation Classification · 92% confidence The document is a slide-based “決算説明” presentation dated May 18, 2026, covering fiscal year ending March 2026, including business progress, clinical pipeline highlights, and strategic outlook. It is not a full annual or interim report with statutory financial statements, nor merely an announcement; instead, it is clearly an investor‐oriented presentation deck explaining results and future strategy. Therefore, it best fits the Investor Presentation category.
2026-05-18 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.